1. Scrip
  2. >>Business
  3. >>Deals

BeiGene Joins Antibody-Drug Conjugate Stampede With DualityBio Deal

 
• By Alaric DeArment

The deal, focused on a preclinical candidate and worth more than $1bn, follows DualityBio’s licensing agreement in April with BioNTech, amid growing interest among drug makers in ADCs.

BeiGene and DualityBio announced an ADC deal • Source: Shutterstock

BeiGene, Ltd. and Duality Biologics aren’t spilling a lot of beans about their licensing deal for a preclinical antibody-drug conjugate (ADC) in solid tumors, but it nevertheless illustrates the growing importance of the drug modality to pharma firms large and small, as well as showing BeiGene’s increasing attention to solid tumors and DualityBio’s interest in pursuing global development of its product candidates.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

First Quarter M&A Activity Rose On The Strength Of Three Deals

 
• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

More from Business

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.